COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-210813/10/2025
-   
  Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements13/10/2025
-   
  Humanitarian Nonprofit Human Appeal USA to Host National Comedy Tour13/10/2025
-   
  Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 202513/10/2025
-   
  ITM Appoints Annette Breunig as Chief People Officer13/10/2025
-   
  Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference13/10/2025
-   
  Immuron Q1 FY26 YoY growth13/10/2025
-   
  CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor, Celebrates 50 Years of Global Pharmaceutical Excellence13/10/2025
-   
  Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook13/10/2025
-   
  Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types13/10/2025
-   
  ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States13/10/2025
-   
  Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira13/10/2025
-   
  HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress13/10/2025
-   
  Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with Pembrolizumab in MSI-H Metastatic Colorectal Cancer Patients Refractory to Anti-PD-1 Therapy, at ESMO 202513/10/2025
-   
  AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 202513/10/2025
-   
  bioLytical’s iStatis Syphilis Antibody Test Now Included in the Australian Register of Therapeutic Goods (ARTG)13/10/2025
-   
  Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?13/10/2025
-   
  EarlyHealth Group Acquires CYB3R, Gulf’s Fastest-Growing Cybersecurity Firm12/10/2025
-   
  DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss12/10/2025
Pages